FDA Accepts Supplement for Inavolisib by Genentech
The FDA has accepted a supplemental NDA for Inavolisib submitted by Genentech.
Asset / Drug
Drug and asset intelligence for Inavolisib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
PI3K Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.